Seroquel Marketing Material Meets the FDA
AstraZeneca Warned by FDA About Misleading Seroquel Marketing Material
AstraZeneca working with FDA after drug warning
FDA orders AstraZeneca to change promotions on Seroquel
These articles discuss a letter that was sent to the drug company by the FDA about some of their promotional material, and the company's response to that letter. The material in question was a fact sheet distributed to doctors along with the prescribing information.
I thought it best to just let the articles speak for themselves. If you'd like to follow the issue further, this link should do a Google News search for you.
posted by j. melinn
AstraZeneca working with FDA after drug warning
FDA orders AstraZeneca to change promotions on Seroquel
These articles discuss a letter that was sent to the drug company by the FDA about some of their promotional material, and the company's response to that letter. The material in question was a fact sheet distributed to doctors along with the prescribing information.
I thought it best to just let the articles speak for themselves. If you'd like to follow the issue further, this link should do a Google News search for you.
posted by j. melinn
Labels: bipolar disorder, medication, pharmaceutical companies, schizophrenia
2 Comments:
Jen, I thought this news was especially important because I'm terrified of tardive dyskinesia and I'd definitely want to know which meds might cause it. Those who aren't familiar with TD can follow this link for info from the National Alliance on Mental Illness.
I actually wanted to post something about TD earlier this year (didn't get a chance) when news articles were popping up all over the place about a study that indicated older antipsychotics were as effective as the newer atypical ones in treating shizophrenia. Some stories did mention that the older drugs were more likely to cause TD, but I don't think most people understood what that meant. The big message was that the pharmaceutical companies had duped doctors into prescribing newer drugs that cost 10x as much as older ones that were just as good. I don’t think the average American would agree with that if he/she knew more about TD and the much lower risk of getting it with the atypicals.
Looks like the American Psychiatric Association agrees, at least as far as reimbursement issues are concerned.
This press release is their recommendation that the study not be used to change policy.
Post a Comment
Links to this post:
Create a Link
<< Home